Oppenheimer Maintains Outperform on Avadel Pharmaceuticals, Raises Price Target to $30
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Francois Brisebois has maintained an 'Outperform' rating on Avadel Pharmaceuticals (NASDAQ:AVDL) and raised the price target from $29 to $30.
October 31, 2024 | 6:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has maintained an 'Outperform' rating on Avadel Pharmaceuticals and increased the price target from $29 to $30, indicating positive sentiment.
The increase in price target from $29 to $30 by Oppenheimer suggests a positive outlook for Avadel Pharmaceuticals. The 'Outperform' rating indicates that the analyst expects the stock to perform better than the market average, which could lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100